



COMPANY PRESENTATION

Fidia Farmaceutici S.p.A.

REGENERATE & EVOLVE.

www.fidiapharma.com

OUR ESSENCE.

MISSION

Our mission is to **leverage scientific opportunities** to provide innovative solutions that **regenerate people's true quality of life.**

VISION

Our vision is to evolve the **healthcare culture** for people living today, to answer the challenges they'll face tomorrow.

PURPOSE

Our purpose is to ensure that all people go beyond seeking good health to reach a **fuller sense of well-being** too.

AN OVERVIEW.

Starting from life to improve
people's true quality of life.

We are an Italian multinational company established in 1946, a pioneer player that has developed the building blocks of **Hyaluronic Acid knowledge** well ahead of its time.

We operate across different therapeutic areas, focusing on **commonly occurring pathologies** with **social** and **economic impact**, **age-related diseases** and other **health-related conditions**, through subsidiaries and partnerships with local distributors.



1.700+ employees
20+ nationalities globally.



510+ millions €
48% generated
in foreign markets.




1.400+ international patents,
of which 1.200+ involve
Hyaluronic Acid.




Development of technology
platforms, pharmaceutical
products, medical devices and
“lifestyle” products, mainly based
on **Hyaluronic Acid (HA)** and its
patented derivatives.

MILESTONES.



MILESTONES: FINANCIAL OPERATIONS.




OUR FOCUS.

We leverage decades of expertise across multiple **therapeutic areas** capitalizing on the unique properties of **Hyaluronic Acid** and its ability to promote **regeneration**.

While placing a **strong focus** on **Joint Care**, **Skin Care** (including **Derma**, **Wound** and **Aesthetic Care**), **Eye Care**, **Specialty Care** (including **Gynaecology**, **Urology**, **Neuroscience**, **Anti-Infectives** and **Cardiovascular**) and **Health & Wellness Care**, we are committed to addressing patient needs and improving **people's true quality of life**.

In line with our digital transformation and **forward-thinking approach**, we have recently launched a multichannel project in Italy to strengthen relationships with healthcare professionals and promote our established assets.



A PATIENT CENTRIC APPROACH.

We are committed to **regenerating** people's health through continuous research, development and marketing of **innovative, varied & patient-centred** solutions, thanks to a complex **know-how**.

Technology Platforms:
advanced **tech solutions** that streamline healthcare delivery.


Pharmaceutical Products:
effective medications that address **specific health needs**.

Medical Devices:
remedies to **improve patient care and treatment outcomes**.

Lifestyle Products:
supports to healthy living and **well-being**.

COMPANY CULTURE.

Our **people values** reflect who we are and how we aspire to evolve: they represent the cornerstone of our identity and our approach in relation to all stakeholders.



OUR GLOBAL PRESENCE.

120+ countries

● HQ

● Subsidiaries

- | | |
|-------------------|-------------|
| Austria | Russia |
| Bulgaria (branch) | Slovakia |
| Czech Republic | Spain |
| Egypt | Switzerland |
| France | Turkey |
| Germany | UAE |
| Moldova | UK |
| Poland | USA |
| Romania | |

● Local partners & distributors



OUR PLANTS.



Abano Terme (PD) - HQ

330,000 m² (plant 215.000 m²)

We produce:

- bottles, vials, ampoules, pre-filled syringes
- multidose and single-dose eye drops
- products for topical use (creams, gels, ointments and moist gauzes)
- oral solids (tablets and capsules)
- active pharmaceutical ingredients (APIs), obtained from tissues and by fermentation
- biological medicinal products.

Paderno Dugnano (MI)

7,500 m²

We develop and produce:

- systems for oral & dermal drug delivery: skin patches, rapid-cooling hydrogel, orally dissolving films and thin-film drug delivery
- gauze and liquid filling lines (solutions, foams and sprays).

Monte Giberto (FM)

3,200 m²

We package:

- food supplements (capsules and tablets)
- sterile single-use gauzes for periocular hygiene.





Noto (SR):

21,000 m²

Our Research and Production site is specialized in the study of the production processes of new enzymes, proteins and polysaccharides by fermentation or through biotechnological processes, using non-pathogenic strains.

OUR MANUFACTURING CAPABILITIES.

Wide range of **pharmaceutical forms**: sterile, lyophilized and injectable products, topical formulations, eye-drops (both multi- and single-dose), and solid orals, offering diversified packaging solutions to meet the requirements of our clients and partners.



(Yearly potential production capacity)



A FULLY INTEGRATED COMPANY.

We are a **fully integrated pharmaceutical company**: we are capable of covering our **entire product life cycle** – from research and development to production, logistics, sales and marketing.

We are focused on the development of **therapeutic solutions** that meet the diverse needs of healthcare professionals and patients.



OUR REVENUES IN 2024.



2024: ~510 Million €

OUR R&D EXPERIENCE.

We focus our **R&D activities**, which are equally balanced across all stages of product development - **Discovery phase, Preclinical phase** and **Clinical phase** - in areas of high scientific and commercial promise.

We have many ongoing collaborations with **Italian** and **international centers of excellence**.

50+ projects
running in our two
Research Units
(Abano T. and Noto)

2 ODD FDA
designations
1 ODD EMA
designation

In 2024
99 patents
granted
worldwide

5 new drugs
under development
in different
therapeutic areas
40+ Mio €
in grants obtained

50+ MD
submitted for MDR
certification

Last update Q4 2025

BROAD EXPERTISE IN **H**YALURONIC **A**CID.

Over 60 years of research into Hyaluronic Acid (HA): we are currently at the forefront in the production of both natural and functionalized **Hyaluronic Acid**, using proprietary and validated manufacturing processes.

25 K+ **SUBJECTS**

Involved in studies investigating HA in **Joint Care**, **Skin Care**, **Eye Care**, **Aesthetic Care**, **Urology**

20 MIO+ **PATIENTS**

Treated with **intra-articular HA-based** products so far*

ONGOING **CLINICAL TRIALS**

United States of America
&
Europe: Czech Republic, Slovakia, France, Poland, Austria, Germany, Italy, Spain

*Since launch of first product in 1987

THE KNOW HOW OF HYALURONIC ACID.

Our know-how of **Hyaluronic Acid** has enabled the company to obtain a variety of **patented chemical modifications** of the native molecule, among them:

HYDEAL-D

- improves mucosal adhesion
- improves resistance to degradation
- provides slow and continuous release of hyaluronic acid. (first to file: 1985)

ACP (Auto-Crosslinked Polymer)

- auto-crosslinking with no chemical spacer between chains
- used where there is a need for a biocompatible, biodegradable, viscoelastic material with improved mechanical properties. (first to file: 1988)


MO.RE. (MOBILE RETiculum)




- first linear, HA amide derivative
- longer residence time
- remarkable rheological properties. (first to file: 1998)

Mu.C.H. (Multi Crosslinked Hyaluronan)

- perfect physical association of two crosslinked derivatives
- diversified bioavailability timing. (first to file: 2009)



OUR PIPELINE.



Various stages of clinical development for the treatment of different diseases.

QUALITY MANAGEMENT SYSTEM.

We are periodically inspected by **different health authorities** , with a **Quality System** that complies with national and international regulatory requirements and the highest safety standards, such as:

- **EU GMP**
- **21 CFR Part 211 and 21 CFR Part 820.**

In addition, the quality system is certified according to **ISO 9001:2015** and **ISO 13485:2016.**

We joint Medical Device Single Audit Program (**MDSAP**) in order to market its medical devices in the USA, Canada, Brazil and Australia.



HEALTH, SAFETY & ENVIRONMENT.

We are committed to improving **workplace conditions and ensuring the sustainability of our activities**. We prioritize the health and safety of our employees.

We conduct yearly risk assessments and implement prevention policies and actions, such as the **ISO 14001** management system, for our plants.

We voluntarily adhere to the **Responsible Care program** to promote sustainable development within the global chemical industry.

Through an **EcoVadis** annual assessment we aim at measuring and improving our sustainability performance across the value chain.





www.fidiapharma.com